Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Bevacimab 400
Healthcare Pharmaceuticals Ltd.
Generic: Bevacizumab
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Bevacimab 400. Please consult your doctor.
CONSULT YOUR DOCTOR
Bevacimab 400 may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
CONSULT YOUR DOCTOR
Bevacimab 400 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
UNSAFE
Bevacimab 400 may cause side effects which could affect your ability to drive.
Sleepiness and fainting have been reported with Bevacimab 400 and this may impair your ability to drive.
SAFE IF PRESCRIBED
Bevacimab 400 is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Bevacimab 400 may not be needed in these patients. Please consult your doctor.
SAFE IF PRESCRIBED
Bevacimab 400 is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Bevacimab 400 may not be needed in these patients. Please consult your doctor.
Medicine Overview of Bevacimab 400mg/16ml Injection
Introduction
Bevacimab 400 is an anticancer medication. It is used in the treatment of cancer of colon and rectum, non-small cell lung cancer, kidney cancer, brain tumor, ovarian and cervical cancer. It helps to prevent the growth of new blood vessels that feed tumors and stops tumors from growing. Bevacimab 400 is an effective medicine, first-line option when used together with other cancer medicines. It is given as an infusion. That means you get it through a small needle in your vein or through a port, which is a device placed under your skin. The doctor will decide your dose and...
... Show moreUses of Bevacimab 400
- Cancer of colon and rectum
- Non-small cell lung cancer
- Kidney cancer
- Brain tumor
- Ovarian cancer
- Cervical cancer
Side effects of Bevacimab 400
Common
- Rectal bleeding
- Taste change
- Headache
- Nosebleeds
- Back pain
- Dry skin
- High blood pressure
- Protein in urine
- Inflammation of the nose
How to use Bevacimab 400
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Bevacimab 400 works
Bevacimab 400 is a anti-angiogenic medication. It works by blocking a protein called vascular endothelial growth factor (VEGF). This stops the formation of blood vessels that bring oxygen and nutrients to cancerous cells.
What if you forget to take Bevacimab 400?
If you miss a dose of Bevacimab 400, please consult your doctor.
Quick Tips
- Bevacimab 400 is an effective, first-line option when used together with other medicines for certain types of cancers such as colorectal, lung, cervical, and kidney cancers.
- Bevacimab 400 is given as an infusion. Your doctor or nurse will monitor you for signs of an infusion reaction such as high blood pressure and trouble breathing.
- It can lower your wound healing ability. Inform your doctor that you are taking this medication before undergoing any surgical procedure.
- It can increase the risk of bleeding. Inform your doctor if you notice any unusual bleeding or bleeding that doesn't stop easily.
- Your doctor may regularly check your blood pressure and levels of protein in your urine while you are on Bevacimab 400.
Brief Description
Indication
Colo-rectal cancer, Lung cancers, Renal cancers, Ovarian cancers, Breast cancers, glioblastoma multiforme of the brain, Exudative ARMD
Administration
IV Preparation
Aseptically withdraw necessary amount & dilute in a total volume of 100 mL NS
Diluted solutions for infusion may be stored at 2-8°C for 8 hr
IV Administration
Do not administer as IV push or bolus; administer only as an IV infusion
Do not initiate until at least 28 days following major surgery; wait until the surgical incision has fully healed
Deliver first infusion over 90 min IV; if well-tolerated, second infusion may be administered over 60 min & each subsequent infusion, over 30 min if 60 min infusion tolerated
Adult Dose
General: Bevacizumab should be prepared by a healthcare professional using aseptic technique. The initial Bevacizumab dose should be delivered over 90 min as an IV infusion. If the 1st infusion is well tolerated, the 2nd infusion may be administered over 60 min. If the 60-min infusion is well tolerated, all subsequent infusions may be administered over 30 min. Dose reduction of Bevacizumab for adverse events is not recommended. If indicated, Bevacizumab should either be permanently discontinued or temporarily suspended. Metastatic Colorectal Cancer (mCRC): The recommended dose of Bevacizumab, administered as an IV infusion, is as follows: First-line Treatment: 5 mg/kg...
... Show moreContraindication
Hypersensitivity to any component
Recent hemoptysis
Mode of Action
Bevacizumab binds to VEGF, the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells.
Neutralising the biological activity of VEGF reduces the vascularisation of tumours, normalises remaining tumour vasculature and inhibits the formation of new tumour vasculature thereby inhibiting tumour growth.
Precaution
Gastrointestinal perforations Gastrointestinal (GI) perforation, fistula formation, and/or intra-abdominal abscess unrelated to therapy duration reported in patients with colorectal cancer as well as other types of cancers Typical presentation reported as abdominal pain associated with symptoms such as constipation and vomiting Include GI perforation in the differential diagnosis of patients presenting with abdominal pain Discontinue therapy permanently in patients with GI perforation Wound healing complications Administration may result in the development of fatal wound dehiscence Discontinue therapy in patients with wound dehiscence requiring medical intervention Hemorrhage Fatal pulmonary hemorrhage can occur in patients with non-small cell lung cancer treated with...
... Show moreSide Effect
>10% Weakness (73-74%),Hypertension (23-67%; grades 3/4: 8-18%),Pain (61-62%),Abdominal pain (50-61%; grades 3/4: 8%),Vomiting (47-52%, grades 3/4:6-11%),URI (40-47%),Constipation (29-40%),Leukopenia (grades 3/4: 37%),Proteinuria (36%, grades 3/4: 3%),Epistaxis (32-35%),Ovarian failure (with mFolfox) (34%),Diarrhea (grades 3/4: 2-34%),Stomatitis (30-32%),Alopecia (6-32%),Neutropenia (grades 3/4: 6-27%),Headache (26%; grades 3/4: 2-4%),Dyspnea (25-26%),Dizziness (19-26%),GI hemorrhage (19-24%),Dyspepsia (17-24%),Taste alteration (14-21%),Dry skin (7-20%),Exfoliative dermatitis (3-19%),Fatigue (grades 3/4: 5-19%),Flatulence (11-19%),Lacrimation disorder (6-18%),Neuropathy (grades 3/4: 1-17%),Weight loss (15-16%),Hypokalemia (12-16%),Skin discoloration (2-16%),Thromboembolic events (grades 3/4: 15%),Myalgia (8-15%),Hypotension (7-15%),Nausea (grades 3/4: 4-12%),Back pain (undefined) 1-10% Dehydration (grades 3/4: 3-10%),DVT (6-9%; grades 3/4: 9%),Polyuria (3-6%),Bilirubinemia (1-6%),Colitis (1-6%),Confusion (1-6%),Neutropenia (5%),Thrombocytopenia (5%),Xerostomia (4-7%),Ileus (grades 3/4: 4-5%),Abnormal gait (1-5%),Bone pain...
... Show morePregnancy Category Note
Pregnancy Based on findings from animal studies and its mechanism of action, drug may cause fetal harm in pregnant women Limited postmarketing reports describe cases of fetal malformations with bevacizumab use in pregnancy; however, these reports are insufficient to determine drug associated risks Animal data In animal reproduction studies, IV administration of bevacizumab to pregnant rabbits every 3 days during organogenesis at doses ~1-10 times the clinical dose of 10 mg/kg produced fetal resorptions, decreased maternal and fetal weight gain and multiple congenital malformations including corneal opacities and abnormal ossification of the skull and skeleton including limb and phalangeal defects...
... Show moreInteraction
Irinotecan/5–fluorouracil/leucovorin The incidence of epistaxis and grade 1 or 2 hemorrhage (including GI hemorrhage, minor gum bleeding, vaginal hemorrhage) was greater in patients receiving bevacizumab plus irinotecan/5-fluorouracil/leucovorin compared with patients receiving irinotecan/5-fluorouracil/leucovorin plus placebo. Closely monitor the patient during coadministration. Live vaccines The administration of live vaccines to patients receiving bevacizumab may result in a reduced immune response. Avoid coadministration. Paclitaxel Decreased paclitaxel exposure was seen when paclitaxel/carboplatin was given in combination with bevacizumab. Closely monitor the patient during coadministration. Sunitinib Coadministration of bevacizumab and sunitinib has been reported to cause unexpected severe toxicity (eg, microangiopathic hemolytic anemia). Coadministration of...
... Show moreব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
